Literature DB >> 17432892

Proteomic analysis reveals a metabolism shift in a laboratory fluconazole-resistant Candida albicans strain.

Lan Yan1, Jun-Dong Zhang, Yong-Bing Cao, Ping-Hui Gao, Yuan-Ying Jiang.   

Abstract

Multifactorial and multistep alterations are involved in acquired fluconazole (FLC) resistance in Candida albicans. In this study, a FLC-resistant C. albicans strain was obtained by serial cultures of a FLC-susceptible C. albicans strain in incrementally increasing concentrations of FLC. The comparative proteomic study, confirmed by real-time RT-PCR, was performed with the susceptible parental strain and the resistant daughter strain to identify proteins altered during the development of FLC resistance. Our analysis of the differentially expressed proteins identified 22 different proteins, most of which were related to energy metabolisms (e.g., Pgk1, Fba1, and Adh1), and some of which have been previously identified as being involved in FLC resistance in C. albicans (e.g., Ald5, Cdc19, and Gap1). Functional analysis revealed lower intracellular ATP level and mitochondrial membrane potential, less endogenous reactive oxygen species generation in response to antifungal agents, and identical susceptibility to exogenous hydrogen peroxide, heat, and hyperosmotic shock in the resistant strain compared with the susceptible strain. Our results suggest that a metabolism shift might contribute to FLC resistance in C. albicans.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17432892     DOI: 10.1021/pr060656c

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  8 in total

1.  Gain-of-function mutations in the transcription factor MRR1 are responsible for overexpression of the MDR1 efflux pump in fluconazole-resistant Candida dubliniensis strains.

Authors:  Sabrina Schubert; P David Rogers; Joachim Morschhäuser
Journal:  Antimicrob Agents Chemother       Date:  2008-09-22       Impact factor: 5.191

2.  Fungicidal drugs induce a common oxidative-damage cellular death pathway.

Authors:  Peter Belenky; Diogo Camacho; James J Collins
Journal:  Cell Rep       Date:  2013-02-14       Impact factor: 9.423

3.  Transcriptional response of Candida albicans biofilms following exposure to 2-amino-nonyl-6-methoxyl-tetralin muriate.

Authors:  Rong-mei Liang; Yong-bing Cao; You-jun Zhou; Yi Xu; Ping-hui Gao; Bao-di Dai; Feng Yang; Hui Tang; Yuan-ying Jiang
Journal:  Acta Pharmacol Sin       Date:  2010-04-12       Impact factor: 6.150

4.  Changes in the proteome of Candida albicans in response to azole, polyene, and echinocandin antifungal agents.

Authors:  Christopher F Hoehamer; Edwin D Cummings; George M Hilliard; P David Rogers
Journal:  Antimicrob Agents Chemother       Date:  2010-02-09       Impact factor: 5.191

5.  Proteomic analysis of Mrr1p- and Tac1p-associated differential protein expression in azole-resistant clinical isolates of Candida albicans.

Authors:  Christopher F Hoehamer; Edwin D Cummings; George M Hilliard; Joachim Morschhäuser; P David Rogers
Journal:  Proteomics Clin Appl       Date:  2009-08       Impact factor: 3.494

6.  Combination of Miconazole and Domiphen Bromide Is Fungicidal against Biofilms of Resistant Candida spp.

Authors:  Jana Tits; Freya Cools; Kaat De Cremer; Katrijn De Brucker; Judith Berman; Kristof Verbruggen; Bert Gevaert; Paul Cos; Bruno P A Cammue; Karin Thevissen
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

7.  ABC transporter Cdr1p contributes more than Cdr2p does to fluconazole efflux in fluconazole-resistant Candida albicans clinical isolates.

Authors:  Ann R Holmes; Ya-Hsun Lin; Kyoko Niimi; Erwin Lamping; Mikhail Keniya; Masakazu Niimi; Koichi Tanabe; Brian C Monk; Richard D Cannon
Journal:  Antimicrob Agents Chemother       Date:  2008-08-18       Impact factor: 5.191

8.  Systems biology of fungal infection.

Authors:  Fabian Horn; Thorsten Heinekamp; Olaf Kniemeyer; Johannes Pollmächer; Vito Valiante; Axel A Brakhage
Journal:  Front Microbiol       Date:  2012-04-02       Impact factor: 5.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.